The Endocrine Society officially submitted its comprehensive response to the Centers for Medicare and Medicaid Services (CMS) on September 11, addressing the proposed updates to the Medicare Physician Fee Schedule (MPFS) for Calendar Year 2027. This annual regulatory process, which dictates the reimbursement landscape for physicians across the United States, has become a focal point for medical societies seeking to balance inflationary pressures with the technical requirements of specialized patient care. In its formal comments, the Society highlighted a paradoxical outlook for the coming year: while the endocrinology specialty is slated for a 2.5% increase in its specific valuation, this gain is currently offset by a proposed 2.5% reduction in the universal conversion factor that applies to all physician services under Medicare Part B.
The Annual Rulemaking Cycle and Regulatory Chronology
The release of the MPFS proposed rule initiates a highly structured period of public discourse and technical review. The process began earlier this summer when CMS published the draft regulations, outlining the agency’s priorities for the 2027 fiscal period. Following the publication, a 60-day public comment period allowed stakeholders, including the Endocrine Society, to analyze the thousands of pages of regulatory text and provide evidence-based feedback.
The Society’s submission on September 11 was the culmination of months of internal data analysis and collaboration. The Clinical Affairs Core Committee (CACC) played a pivotal role in this process, reviewing the proposed changes to ensure they reflect the clinical realities of modern endocrine practice. This committee, composed of practicing endocrinologists and policy experts, provided the technical expertise necessary to challenge or support specific coding changes.
The timeline now shifts toward the finalization phase. CMS is expected to review the thousands of comments submitted by medical associations, hospital systems, and patient advocacy groups before releasing the Final Rule by early November. Once finalized, the new payment policies and rates will take effect on January 1, 2027, unless interrupted by legislative action from the United States Congress.
The Conversion Factor and the Quest for Inflationary Adjustments
One of the most pressing issues addressed in the Society’s letter is the proposed 2.5% decrease in the Medicare conversion factor. The conversion factor is the dollar amount that CMS multiplies by the Relative Value Units (RVUs) assigned to a service to determine the final payment rate. Under current law, the MPFS is subject to "budget neutrality" requirements, meaning that any increases in spending in one area must be offset by cuts elsewhere.
For over a decade, this mechanism has resulted in stagnant or declining conversion factors, even as the cost of running a medical practice has surged. The Endocrine Society, alongside a broad coalition of physician organizations, is urging Congress to intervene. The Society’s position is that the conversion factor should be tied to the Medicare Economic Index (MEI), a measure of practice cost inflation.
Data from the American Medical Association (AMA) suggests that when adjusted for inflation in practice costs, Medicare physician payment has effectively declined by 29% between 2001 and 2024. The Endocrine Society argues that without an annual inflationary update, the sustainability of independent practices and the ability of hospital systems to maintain specialty departments are at significant risk. The proposed 2.5% cut for 2027 would further exacerbate this trend, potentially limiting patient access to specialized endocrine care.
Advancements in Diagnostic Reimbursement: The FNA Success
Despite the broader concerns regarding the conversion factor, the 2027 proposed rule contains a significant victory for endocrinologists who perform Fine Needle Aspirations (FNA). CMS has proposed the creation of a new practice expense equipment item, designated as ER130, for "Fine Needle Aspiration portable ultrasound."
This proposal is the result of a multi-year advocacy effort by the Endocrine Society, working in tandem with other medical societies at the Current Procedural Terminology (CPT) and Relative Value Scale Update Committee (RUC) levels. The inclusion of a dedicated equipment item for portable ultrasound reflects the evolution of thyroid and parathyroid diagnostics. In modern endocrinology, the use of point-of-care ultrasound during FNA procedures is no longer an outlier but a standard of care that improves diagnostic accuracy and patient safety.
By recognizing ER130 as a specific practice expense input, CMS acknowledges the capital costs associated with maintaining high-quality ultrasound equipment in an office setting. This change is expected to stabilize and potentially increase the practice expense component of the reimbursement for FNA services, ensuring that endocrinologists can continue to offer these essential diagnostic procedures in-house rather than referring patients to radiology departments, which often increases the total cost of care to the Medicare program.
The G2211 Conflict: Complex Care vs. Administrative Simplification
A major point of contention in the Society’s comments involves the fate of the G2211 healthcare common procedure coding system (HCPCS) code. Originally introduced to capture the inherent complexity of longitudinal care for patients with chronic conditions, G2211 has been a vital tool for endocrinologists managing diseases like diabetes, osteoporosis, and adrenal disorders.
In the 2027 proposed rule, CMS has suggested deleting G2211 and replacing it with a new modifier code, currently referred to as MOD1. Under this proposal, when MOD1 is appended to an Evaluation and Management (E/M) code, it would trigger a 16% increase in the payment for that specific CPT code. While this may seem like an administrative simplification, the Endocrine Society has expressed deep concern regarding its impact on work RVUs.
The Society’s analysis indicates that transitioning from a standalone code to a modifier could result in a net loss of work RVUs, particularly for physicians practicing in large hospital systems and academic medical centers. These institutions often rely on RVU-based productivity models to determine compensation and resource allocation. A reduction in work RVUs could lead to a perceived decrease in the "value" of the endocrinologist’s time, despite the clinical complexity remaining unchanged. The Society’s letter strongly urges CMS to retain G2211, arguing that the code accurately reflects the ongoing, comprehensive care coordination that is the hallmark of endocrine medicine.
Modifier 25 and the Risk of Payment Bundling
The Endocrine Society also addressed a proposal that seeks to reduce payment when Modifier 25 is used in conjunction with certain E/M visits. Modifier 25 is used to indicate that on the day of a procedure or other service, the physician performed a significant, separately identifiable E/M service above and beyond the usual preoperative and postoperative care associated with the procedure.
CMS has historically scrutinized the use of Modifier 25, citing concerns about "overlapping" work. However, the Endocrine Society argues that in a specialty like endocrinology, patients often present with multiple complex issues. A patient may visit for a scheduled procedure, such as a biopsy, but also require a detailed consultation regarding a change in their insulin pump settings or a new thyroid symptom.
The proposed reduction in payment for these dual-service visits is viewed by the Society as a move toward "bundling" that fails to account for the distinct clinical work performed. Reducing reimbursement for these instances could discourage physicians from addressing multiple patient needs in a single visit, potentially forcing patients to schedule separate appointments, which increases the burden on the elderly and those with mobility issues.
Broader Implications for the Endocrinology Workforce
The cumulative effect of these proposed changes carries significant weight for the future of the endocrinology workforce. Currently, endocrinology is one of the lower-compensated specialties in medicine, which has contributed to a growing shortage of specialists. According to the Association of American Medical Colleges (AAMC), the demand for endocrinologists is expected to outpace supply significantly over the next decade, driven by the rising prevalence of diabetes and metabolic disorders.
The Society argues that the 2.5% specialty-specific increase proposed for 2027 is a step in the right direction but is insufficient if the base conversion factor continues to erode. If the G2211 code is deleted and Modifier 25 payments are reduced, the financial viability of specializing in endocrinology becomes even more challenging for medical students and residents facing high levels of debt.
The Society’s advocacy emphasizes that Medicare’s payment policies do not exist in a vacuum; they often set the standard for private payers as well. Therefore, a decrease in Medicare reimbursement can trigger a downward trend across the entire payer landscape, impacting the ability of clinics to hire support staff, invest in new technologies, and provide the time-intensive care required for complex endocrine patients.
Collaboration and Advocacy Infrastructure
The drafting of the 11-page comment letter was a collaborative effort involving the Endocrine Society’s professional staff and the CACC. This internal infrastructure allows the Society to respond to complex federal regulations with high-level clinical data. The Society also frequently collaborates with the Council of Medical Specialty Societies (CMSS) to ensure that the voice of specialty medicine is unified when approaching CMS and Congress.
In addition to the formal letter to CMS, the Society is mobilizing its membership to engage in direct advocacy with their representatives. The push for a permanent fix to the Medicare payment system—specifically the transition to an MEI-based update—remains the Society’s top legislative priority.
Conclusion and Next Steps
As the medical community awaits the final rule in November, the Endocrine Society remains vigilant. The proposed 2027 MPFS represents a critical juncture for the specialty, balancing the technical recognition of FNA procedures against the broader systemic threats posed by conversion factor cuts and the restructuring of complex care codes.
Physicians and stakeholders are encouraged to review the full text of the Society’s submission on the official website, as it contains detailed technical arguments regarding RVU calculations and practice expense inputs. The outcome of this regulatory cycle will not only determine the reimbursement rates for the year 2027 but will also signal CMS’s long-term strategy for valuing cognitive specialties in an increasingly complex healthcare environment. The Society’s stance is clear: while procedural updates like ER130 are welcomed, they cannot come at the expense of the foundational payment structures that support the long-term, complex management of endocrine patients.
